Literature DB >> 11672897

Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine.

E de Kleijn1, L van Eijndhoven, C Vermont, B Kuipers, H van Dijken, H Rümke, R de Groot, L van Alphen, G van den Dobbelsteen.   

Abstract

A clinical phase II trial with the RIVM hexavalent OMV vaccine containing six different PorAs was carried out in toddlers (2-3 years) and schoolchildren (7-8 years) in The Netherlands. Children were vaccinated three times (0, 2, 8 months). Sera after two and three vaccinations were analysed for serum bactericidal activity (SBA) and isotype distribution in whole cell enzyme linked immunosorbent assay (ELISA). The SBA after vaccination against the six PorAs was significantly different. We investigated whether the age specific and PorA specific differences in SBA titers correlated with differences in PorA specific IgG isotype distribution. The SBA titers were higher in toddlers compared with schoolchildren. After vaccination, IgG1 antibodies dominated the response followed by IgG3 antibodies. IgG2 levels were low, whereas IgG4 was not detected. Irrespective of PorA, IgG total and isotype specific titers after two and three vaccinations were significantly higher in toddlers than in schoolchildren. A weak correlation was found between IgG total or IgG1 and SBA. Although the immunogenicity of the six PorAs is very different, the isotype distribution was similar for all six tested PorAs. We conclude that the RIVM hexavalent PorA vesicle vaccine induces bactericidal antibodies mainly of the IgG1 and IgG3 isotypes that are considered to be most important for protection against disease. The isotype distribution of the response is not age-dependent.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11672897     DOI: 10.1016/s0264-410x(01)00371-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  Characterization of MspA, an immunogenic autotransporter protein that mediates adhesion to epithelial and endothelial cells in Neisseria meningitidis.

Authors:  D P J Turner; A G Marietou; L Johnston; K K L Ho; A J Rogers; K G Wooldridge; D A A Ala'Aldeen
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

Review 2.  Outer membrane vesicles for vaccination and targeted drug delivery.

Authors:  Sihan Wang; Jin Gao; Zhenjia Wang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-04-26

3.  Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in studies of infants.

Authors:  N Ruijne; R A Lea; J O'Hallahan; P Oster; D Martin
Journal:  Clin Vaccine Immunol       Date:  2006-07

4.  Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.

Authors:  C L Vermont; H H van Dijken; C J P van Limpt; R de Groot; L van Alphen; G P J M van Den Dobbelsteen
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

5.  Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation form.

Authors:  Thomas A Luijkx; Harry van Dijken; Hendrik-Jan Hamstra; Betsy Kuipers; Peter van der Ley; Loek van Alphen; Germie van den Dobbelsteen
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

6.  Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin.

Authors:  Frances Bowe; Ed C Lavelle; Edel A McNeela; Christine Hale; Simon Clare; Beatrice Arico; Marzia M Giuliani; Aaron Rae; Alan Huett; Rino Rappuoli; Gordon Dougan; Kingston H G Mills
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

7.  Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines.

Authors:  Synne Sandbu; Berit Feiring; Philipp Oster; Oddveig S Helland; Hilde S W Bakke; Lisbeth M Naess; Audun Aase; Ingeborg S Aaberge; Anne-Cathrine Kristoffersen; Kjersti M Rydland; Sandrine Tilman; Hanne Nøkleby; Einar Rosenqvist
Journal:  Clin Vaccine Immunol       Date:  2007-07-18

8.  Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.

Authors:  Andrew R Gorringe; Stephen Taylor; Charlotte Brookes; Mary Matheson; Michelle Finney; Moyra Kerr; Michael Hudson; Jamie Findlow; Ray Borrow; Nick Andrews; George Kafatos; Cariad M Evans; Robert C Read
Journal:  Clin Vaccine Immunol       Date:  2009-06-24

9.  Improved production process for native outer membrane vesicle vaccine against Neisseria meningitidis.

Authors:  Bas van de Waterbeemd; Gijsbert Zomer; Patricia Kaaijk; Nicole Ruiterkamp; René H Wijffels; Germie P J M van den Dobbelsteen; Leo A van der Pol
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

10.  Modeling Neisseria meningitidis metabolism: from genome to metabolic fluxes.

Authors:  Gino J E Baart; Bert Zomer; Alex de Haan; Leo A van der Pol; E Coen Beuvery; Johannes Tramper; Dirk E Martens
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.